Boston Scientific to Acquire Axonics for $3.7B
Ticker: BSX · Form: 8-K · Filed: Nov 22, 2024 · CIK: 885725
| Field | Detail |
|---|---|
| Company | Boston Scientific CORP (BSX) |
| Form Type | 8-K |
| Filed Date | Nov 22, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, medical-devices, urology
Related Tickers: AXNX
TL;DR
BSX is buying Axonics for $3.7B to boost its urology business. Deal expected to close H1 2025.
AI Summary
Boston Scientific Corporation announced on November 19, 2024, that it has entered into a definitive agreement to acquire Axonics, Inc. for approximately $3.7 billion in cash. The acquisition is expected to close in the first half of 2025, subject to customary closing conditions, including regulatory approvals and the approval of Axonics stockholders. This strategic move aims to expand Boston Scientific's urology portfolio.
Why It Matters
This acquisition significantly expands Boston Scientific's presence in the urology market, potentially leading to new product offerings and increased competition in the medical device sector.
Risk Assessment
Risk Level: medium — The acquisition is subject to regulatory approvals and stockholder approval, which introduces uncertainty regarding its completion and timing.
Key Numbers
- $3.7B — Acquisition Price (Total cash consideration for Axonics, Inc.)
- H1 2025 — Expected Closing (Anticipated timeframe for the acquisition to be finalized.)
Key Players & Entities
- Boston Scientific Corporation (company) — Acquiring company
- Axonics, Inc. (company) — Target company
- $3.7 billion (dollar_amount) — Acquisition price
- November 19, 2024 (date) — Agreement date
- first half of 2025 (date) — Expected closing period
FAQ
What is the primary strategic rationale behind Boston Scientific's acquisition of Axonics?
The acquisition is intended to expand Boston Scientific's urology portfolio.
What is the total value of the proposed acquisition?
Boston Scientific has agreed to acquire Axonics for approximately $3.7 billion in cash.
When is the acquisition expected to be completed?
The acquisition is expected to close in the first half of 2025.
What are the key conditions for the acquisition to close?
The acquisition is subject to customary closing conditions, including regulatory approvals and the approval of Axonics stockholders.
What is the ticker symbol for Boston Scientific Corporation?
The ticker symbol for Boston Scientific Corporation is BSX.
Filing Stats: 1,770 words · 7 min read · ~6 pages · Grade level 17.9 · Accepted 2024-11-22 16:18:35
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share BSX New York Stock
Filing Documents
- bsx-20241119.htm (8-K) — 42KB
- ex101-2025annualbonusplan.htm (EX-10.1) — 75KB
- ex102-2025tsrplan.htm (EX-10.2) — 65KB
- ex103-2025organicnetsalesp.htm (EX-10.3) — 28KB
- image1a.jpg (GRAPHIC) — 5KB
- image3a.jpg (GRAPHIC) — 5KB
- image5a.jpg (GRAPHIC) — 2KB
- imagea.jpg (GRAPHIC) — 5KB
- 0000885725-24-000081.txt ( ) — 427KB
- bsx-20241119.xsd (EX-101.SCH) — 3KB
- bsx-20241119_def.xml (EX-101.DEF) — 15KB
- bsx-20241119_lab.xml (EX-101.LAB) — 27KB
- bsx-20241119_pre.xml (EX-101.PRE) — 16KB
- bsx-20241119_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1* Boston Scientific Corporation 2025 Annual Bonus Plan, effective as of January 1, 2025 10.2* Boston Scientific Corporation 2025 Relative Total Shareholder Return Performance Share Program 10.3* Boston Scientific Corporation 2025 Organic Net Sales Growth Performance Share Program 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Documents filed or furnished with this report. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 22, 2024 BOSTON SCIENTIFIC CORPORATION By: /s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel and Assistant Secretary